MedPath

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Registration Number
NCT00500318
Lead Sponsor
AstraZeneca
Brief Summary

This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
181
Inclusion Criteria
  • A diagnosis of stable moderate to severe COPD (GOLD 2006); post-levalbuterol FEV1 >=30% and < 80% predicted and FEV1/FVC<70% predicted
  • Current or former cigarette smoker
  • Functional Residual Capacity (FRC) measured by body plethysmography >= 120% of predicted value
  • Baseline Dyspnea Index (BDI) focal score ≤ 7 at Visit 4
Exclusion Criteria
  • History of presence of asthma, allergic rhinitis, or atopy
  • Hospitalization for acute COPD exacerbation in the 3 months prior to study entry
  • Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry
  • Clinically significant respiratory conditions other than COPD
  • Chronic use of oxygen therapy >= 15 hours a day

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
AclidiniumAclidinium Bromide-
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Exercise Endurance Time (ET)From baseline Week 0 (Visit 4) to Week 6 (Visit 6)

Exercise endurance time is defined as the time from the increase in work rate at 75% Wmax (watts) to the point of symptom limitation. The Wmax is defined as the highest work rate the patients were able to maintain for at least 30 seconds.

Secondary Outcome Measures
NameTimeMethod
Trough Forced Expiratory Volume in 1 Second (FEV1)Change from baseline (Visit 4) at Week 6 (Visit 6)

Change in trough Forced Expiratory Volume in 1 second. FEV1 was assessed at the end of the daily dosing interval (Trough).

Trough Inspiratory Capacity (IC)Change from baseline Week 0 (Visit 4) to Week 6 (Visit 6)

Change in trough Inspiratory Capacity. Inspiratory Capacity was measured as part of the spirometry procedures performed at each visit. IC was assessed at the end of the daily dosing interval (Trough).

Functional Residual Capacity (FRC)Change from baseline Week 0 (Visit 4) to Week 6 (Visit 6)

Change in trough Functional Residual Capacity. FRC was assessed at the end of the daily dosing interval (Trough).

Inspiratory Capacity (IC)/Total Lung Capacity (TLC) RatioChange from baseline Week 0 (Visit 4) to Week 6 (Visit 6)

Ratio of trough Inspiratory Capacity verses Total Lung Capacity.

Trial Locations

Locations (52)

Forest Investigative Site 0974

🇺🇸

Pensacola, Florida, United States

Forest Investigative Site 0988

🇺🇸

Sacramento, California, United States

Forest Investigative Site 0887

🇺🇸

Los Angeles, California, United States

Forest Investigative Site 0980

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 0991

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 0898

🇺🇸

Baltimore, Maryland, United States

Forest Investigative Site 0888

🇺🇸

Philadelphia, Pennsylvania, United States

Forest Investigative Site 0893

🇨🇦

Ste-Foy, Quebec, Canada

Forest Investigative Site 2204

🇨🇦

Ottawa, Ontario, Canada

Forest Investigative Site 0962

🇺🇸

Nashville, Tennessee, United States

Forest Investigative Site 0909

🇺🇸

Phoenix, Arizona, United States

Forest Investigative Site 2071

🇺🇸

Omaha, Nebraska, United States

Forest Investigative Site 1057

🇺🇸

Hershey, Pennsylvania, United States

Forest Investigative Site 2088

🇺🇸

Jasper, Alabama, United States

Forest Investigative Site 2663

🇺🇸

Clearwater, Florida, United States

Forest Investigative Site 0973

🇺🇸

Los Angeles,, California, United States

Forest Investigative Site 2008

🇺🇸

Marietta, Georgia, United States

Forest Investigative Site 1030

🇺🇸

Jacksonville, Florida, United States

Forest Investigative Site 0987

🇺🇸

Austell, Georgia, United States

Forest Investigative Site 0984

🇺🇸

Iowa City, Iowa, United States

Forest Investigative Site 0886

🇺🇸

Boston, Massachusetts, United States

Forest Investigative Site 0889

🇺🇸

Livonia, Michigan, United States

Forest Investigative Site 1029

🇺🇸

N. Dartmouth, Massachusetts, United States

Forest Investigative Site 2079

🇺🇸

St. Charles, Missouri, United States

Forest Investigative Site 0972

🇺🇸

Brooklyn, New York, United States

Forest Investigative Site 0971

🇺🇸

Great Neck, New York, United States

Forest Investigative Site 0688

🇺🇸

Charlotte, North Carolina, United States

Forest Investigative Site 1114

🇺🇸

New York, New York, United States

Forest Investigative Site 2665

🇺🇸

New York, New York, United States

Forest Investigative Site 2081

🇺🇸

Charlotte, North Carolina, United States

Forest Investigative Site 2072

🇺🇸

Charleston, South Carolina, United States

Forest Investigative Site 0979

🇺🇸

Columbia, South Carolina, United States

Forest Investigative Site 1107

🇺🇸

Columbia, South Carolina, United States

Forest Investigative Site 0983

🇺🇸

Scranton, Pennsylvania, United States

Forest Investigative Site 1078

🇺🇸

Greenville, South Carolina, United States

Forest Investigative Site 1082

🇺🇸

Dallas, Texas, United States

Forest Investigative Site 0890

🇺🇸

Houston, Texas, United States

Forest Investigative Site 2058

🇺🇸

Dallas, Texas, United States

Forest Investigative Site 0968

🇨🇦

Edmonton, Alberta, Canada

Forest Investigative Site 0960

🇨🇦

Kelowna, British Columbia, Canada

Forest Investigative Site 0977

🇺🇸

Midvale, Utah, United States

Forest Investigative Site 0905

🇨🇦

Vancouver, British Columbia, Canada

Forest Investigative Site 0976

🇨🇦

Winnipeg, Manitoba, Canada

Forest Investigative Site 2205

🇨🇦

Montreal, Quebec, Canada

Forest Investigative Site 0891

🇨🇦

Hamilton, Ontario, Canada

Forest Investigative Site 0969

🇨🇦

Windsor, Ontario, Canada

Forest Investigative Site 0943

🇨🇦

Saskatoon, Saskatchewan, Canada

Forest Investigative Site 0957

🇺🇸

Long Beach, California, United States

Forest Investigative Site 0885

🇺🇸

Torrance, California, United States

Forest Investigative Site 0981

🇺🇸

Toledo, Ohio, United States

Forest Investigative Site 1080

🇺🇸

Topeka, Kansas, United States

Forest Investigative Site 0900

🇺🇸

Spartanburg, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath